Outcomes of Idecabtagene Vicleucel Therapy in Patients with Relapsed/Refractory Multiple Myeloma: A Single-Institution Experience

<b>Background/Objectives:</b> Idecabtagene vicleucel (ide-cel), an anti-B-cell maturation chimeric antigen receptor T-cell therapy, represents an unprecedented treatment option for relapsed/refractory multiple myeloma (R/R MM). Nevertheless, given its limitations, including the risk of a...

Full description

Bibliographic Details
Published in:Biomedicines
Main Authors: Aaron Trando, Farid Ghamsari, Philip Yeung, Caitlin Costello, Ila Saunders, Ah-Reum Jeong
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Subjects:
CAR T-cell therapy
ide-cel
multiple myeloma
CRS
ICANS
cytomegalovirus
Online Access:https://www.mdpi.com/2227-9059/13/1/36

Internet

https://www.mdpi.com/2227-9059/13/1/36

Similar Items